Background and purpose: In the SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), ticagrelor was not superior to aspirin. 1). Ticagrelor (trade name Brilinta, Brilique, and formerly Possia) is a pharmaceutical drug used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries.It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor. In this study, ticagrelor … Patients are randomized 1 : 1 to ticagrelor or aspirin within 24 h of the onset of symptoms of acute ischemic stroke or TIA and followed for 90 days on study drug with an additional 30‐day follow‐up on standard of care (Fig. The SOCRATES trial, which was conducted at 674 centers in 33 countries, compared ticagrelor (Brilinta; AstraZeneca) and aspirin monotherapy in 13,199 patients with nonsevere, noncardioembolic acute ischemic stroke or high-risk TIA who had not received thrombolytic therapy and could be randomized within 24 hours of symptom onset. SOCRATES: Ticagrelor Not Superior to Aspirin for Stroke, TIA. The ticagrelor dose in THALES is the same as that used in the target population of patients with ischemic stroke or TIA in the SOCRATES study, in which ticagrelor was well-tolerated and had a similar safety profile as aspirin with respect to major bleeding events.

Ticagrelor was administered as a 180-mg … SOCRATES was a randomised, double-blind, controlled trial of ticagrelor versus aspirin in patients aged 40 years or older with a non-cardioembolic, non-severe acute ischaemic stroke, or high-risk transient ischaemic attack from 674 hospitals in 33 countries. 4,15 In patients with acute coronary syndrome, the same ticagrelor dose was used and treatment with ticagrelor … This means that a 40-cent tablet, first sold by Bayer in 1899, was just as good at helping patients as AZ’s new drug that costs around $7 (before discounts) per daily treatment. Image SOCRATES (Acute Stroke Or Transient IsChaemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES) is a global clinical trial involving 9,600 patients who have experienced an acute… [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] (SOCRATES) The safety and scientific validity of this study is the … Design. Background The SOCRATES study compares ticagrelor versus aspirin for the prevention of major vascular events in patients with acute ischemic stroke or transient ischemic attack [1,2]. The drug is produced by AstraZeneca. Ticagrelor (Brilinta, AstraZeneca) isn’t better secondary prevention for stroke patients than is aspirin, according to top-line results from the SOCRATES trial. At 12 months, the ticagrelor group had lower rates of CV death, MI, or stroke than clopidogrel (9.8% vs. 11.7%). The SOCRATES trial showed that ticagrelor monotherapy with 90 mg BID was not superior to aspirin 100 mg daily in reducing major cardiovascular events in patients presenting with low-acuity ischemic stroke or high-risk transient ischemic attack (TIA). Because of differences in patient demographics and stroke disease pattern in Asia, outcomes of ticagrelor … Following these results, the SOCRATES trial was designed to investigate the comparative efficacy of ticagrelor versus aspirin in reducing a composite endpoint of recurrent stroke, MI, or death at 90 days in patients presenting with acute neurologic ischemia. May 11, 2016. By contrast, a slightly higher major haemorrhagic rate was found in PRINCE than in the Asian subgroup in the SOCRATES trial (1.5% in the ticagrelor/aspirin group in PRINCE v 0.6% in the ticagrelor used as monotherapy in SOCRATES).4 This difference could be related to the combined use of two drugs in our study. Sue Hughes . BACKGROUND AND PURPOSE: SOCRATES (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes), comparing ticagrelor with aspirin in patients with acute cerebral ischemia, found a nonsignificant 11% relative risk reduction for stroke, myocardial infarction, or death (P=0.07). The SOCRATES trial showed that ticagrelor monotherapy with 90 mg BID was not superior to aspirin 100 mg daily in reducing major cardiovascular events in patients presenting with low-acuity ischemic … HOUSTON, TX—It might be worth testing ticagrelor versus aspirin for preventing recurrent events in patients with nonsevere acute ischemic strokes or high-risk TIAs that are related to atherosclerotic disease, a prespecified secondary analysis of the neutral SOCRATES trial suggests. SOCRATES is a multicenter, randomized, double‐blind, double‐dummy, parallel‐group superiority trial.